ahlam1399
08-25-2016, 10:55 AM
**vartis an**unces positive phase III results for MS drug siponimod
ZURICH (Reuters) – **vartis AG said a late-stage study showed its oral, once-daily BAF312, or siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=I2UI9lOz3ME:9tN2bO_BXW8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=I2UI9lOz3ME:9tN2bO_BXW8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=I2UI9lOz3ME:9tN2bO_BXW8:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=I2UI9lOz3ME:9tN2bO_BXW8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=I2UI9lOz3ME:9tN2bO_BXW8:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/I2UI9lOz3ME
ZURICH (Reuters) – **vartis AG said a late-stage study showed its oral, once-daily BAF312, or siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=I2UI9lOz3ME:9tN2bO_BXW8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=I2UI9lOz3ME:9tN2bO_BXW8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=I2UI9lOz3ME:9tN2bO_BXW8:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=I2UI9lOz3ME:9tN2bO_BXW8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=I2UI9lOz3ME:9tN2bO_BXW8:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/I2UI9lOz3ME